E-LIB Suche - Ergebnisse für: Bijou, Fontanet - Sprache DE

Personensuche X

Sortierung: Jahr

Sortierung: Relevanz

1

Challenges for quality and utilization of real-world data f..:

Ghesquières, Hervé ; Cherblanc, Fanny ; Belot, Aurélien...
Blood Advances. 8 (2024) 2 - p. 296-308 , 2024

Link: https://doi.org/10.1182/..

2

Cerebellum/liver index on baseline 18F-FDG PET/CT to improv..:

Morland, David ; Kanagaratnam, Lukshe ; Hubelé, Fabrice...
EJNMMI Research. 14 (2024) 1 - p. , 2024

Link: https://doi.org/10.1186/..

3

Health-related quality of life profile of newly diagnosed p..:

Anota, Amélie ; Basset, Mathurine ; Charton, Emilie...
European Journal of Cancer. 208 (2024) - p. 114210 , 2024

Link: https://doi.org/10.1016/..

4

Final results on effectiveness and safety of Ibrutinib in p..:

Dartigeas, Caroline ; Quinquenel, Anne ; Ysebaert, Loïc...
Annals of Hematology. , 2024

Link: https://doi.org/10.1007/..

5

S149: OTHER MALIGNANCIES IN THE HISTORY OF CLL: THE FINAL A..:

Chatzikonstantinou, Thomas ; Scarfò, Lydia ; Karakatsoulis, Georgios...
HemaSphere. 7 (2023) S3 - p. e24596f8 , 2023

Link: https://doi.org/10.1097/..

6

Long-Term Efficacy and Safety of Zanubrutinib in Patients w..:

Opat, Stephen ; Tedeschi, Alessandra ; Hu, Bei...
Transplantation and Cellular Therapy. 29 (2023) 2 - p. S105-S106 , 2023

Link: https://doi.org/10.1016/..

7

P1080: ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB I..:

Trotman, Judith ; Luigi Zinzani, Pier ; Mayer, Jiri...
HemaSphere. 7 (2023) S3 - p. e2687131 , 2023

Link: https://doi.org/10.1097/..

8

Salvage therapy with brentuximab-vedotin and bendamustine f..:

Aubrais, Raphaelle ; Bouabdallah, Krimo ; Chartier, Loic...
Blood Advances. 7 (2023) 19 - p. 5733-5742 , 2023

Link: https://doi.org/10.1182/..

9

Safety and efficacy of zanubrutinib in relapsed/refractory ..:

Opat, Stephen ; Tedeschi, Alessandra ; Hu, Bei...
Blood Advances. 7 (2023) 22 - p. 6801-6811 , 2023

Link: https://doi.org/10.1182/..

10

Other malignancies in the history of CLL: an international ..:

Chatzikonstantinou, Thomas ; Scarfò, Lydia ; Karakatsoulis, Georgios...
eClinicalMedicine. 65 (2023) - p. 102307 , 2023

Link: https://doi.org/10.1016/..

11

Baseline 18F-FDG Metabolic Tumor Volume Predicts Response t..:

Morland, David ; Kanagaratnam, Lukshe ; Hubelé, Fabrice...
HemaSphere. 7 (2023) 2 - p. e833 , 2023

Link: https://doi.org/10.1097/..

12

S149: OTHER MALIGNANCIES IN THE HISTORY OF CLL: THE FINAL A..:

Chatzikonstantinou, Thomas ; Scarfò, Lydia ; Karakatsoulis, Georgios...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428295/. , 2023

Link: http://www.ncbi.nlm.nih...

13

S149: OTHER MALIGNANCIES IN THE HISTORY OF CLL: THE FINAL A..:

Thomas Chatzikonstantinou ; Lydia Scarfò ; Georgios Karakatsoulis...
http://journals.lww.com/10.1097/01.HS9.0000967508.24596.f8. , 2023

Link: https://doi.org/10.1097/..

14

Randomized Phase III Trial Evaluating Subcutaneous Rituxima..:

Cartron, Guillaume ; Bachy, Emmanuel ; Tilly, Hervé...
info:eu-repo/semantics/altIdentifier/doi/10.1200/JCO.22.02327. , 2023

Link: https://hal.science/hal-..

15

Other malignancies in the history of CLL: an international ..:

Chatzikonstantinou, Thomas ; Scarfò, Lydia ; Karakatsoulis, Georgios...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685149/. , 2023

Link: http://www.ncbi.nlm.nih...

1-15